Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, remains a
global health challenge requiring novel and effective therapeutic agents and approaches. …

Proteasomal deubiquitinase (DUB) inhibition has been found to be effective in experimental
cancer therapy by inducing proteasome inhibition and apoptosis. Ferroptosis is a form of …

Triple-negative breast cancer (TNBC) is a heterogeneous malignancy in women. It is associated
with poor prognosis, aggressive malignant behavior, and limited treatment options. In …

Background/Aims: The ubiquitin proteasome system (UPS) is responsible for the degradation
of most intracellular proteins, and proteasomal deubiquitinases (DUBs) have recently been …

Deubiquitinates (DUBs) have been suggested as novel promising targets for cancer therapies.
Accumulating experimental evidence suggests that some metal compounds have the …

Background Ubiquitin-proteasome system (UPS) is integral to cell survival by maintaining
protein homeostasis, and its dysfunction has been linked to cancer and several other human …

Hyperbilirubinemia may increase the risk of Alzheimer’s disease (AD) but its mechanistic role
in AD pathogenesis remains obscure. Here, we used animal models to investigate the short…

Background Myelodysplastic neoplasms (MDS) are myeloid neoplasms characterized by
disordered differentiation of hematopoietic stem cells and a predisposition to acute myeloid …

Objective: Sorafenib is a first-line drug for advanced hepatocellular carcinoma (HCC).
Unfortunately, most patients with HCC do not respond to sorafenib, mainly because of the frequent …

Fragments of β-lactoglobulin were produced by proteolytic cleavage with trypsin, and
chemical cleavage with cyanogen bromide, followed by gel filtration on Sephadex G-50. The …